Study guide

2.5 Residual Risk & Follow-Up Medical Plans

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.5 Residual Risk & Follow-Up Medical Plans

Key Takeaways Explain This Topic AI

Residual risk is the remaining probability of being a carrier or of an affected pregnancy after negative or uninformative testing, incorporating detection rate limits and untested variant types

Negative carrier screening never implies zero risk when sensitivity is incomplete, not all genes were assayed, or family-specific variants may be missed by the method

Follow-up plans pair residual numbers with actions: partner testing, expanded sequencing, targeted familial-variant testing, prenatal/preimplantation options, or phenotype-first evaluation

When a familial pathogenic variant is known, test for that variant; a negative generic screening panel does not replace site-specific testing

Document assumptions, detection rates, and recommended next steps so residual-risk counseling is clinically actionable and revisable when new results arrive

Last updated: August 2026

2.5 Residual Risk & Follow-Up Medical Plans

Quick Answer: After negative or uninformative results, quote a residual risk (not zero), explain why (detection rate, gene coverage, family-variant mismatch), and attach a follow-up plan : partner testing, expanded/gene-specific testing, site-specific familial testing, prenatal options, or clinical surveillance.

Domain 2A closes the loop from pedigree → Mendelian prior → Bayes → what we do next . A correct residual fraction without a plan is incomplete care and an incomplete exam answer.

What "Residual Risk" Means

Residual risk is the probability that remains after incorporating available negative evidence. Common forms:

  • Residual target Typical setting Driven by
  • Residual carrier probability Negative carrier screen Prior × (1 − detection rate), normalized (Bayes)

Residual affected-pregnancy risk Both partners screened or one known carrier Carrier posteriors × 1/4 (AR) or XL transmission fractions

Residual inheritance risk Negative test for a known familial variant Lab error, rare sample mix-up, or unrecognized alternate molecular mechanism—usually very low if the assay covers the variant

Residual syndromic risk Uninformative panel/exome Phenotypic differential still open; consider alternate genes or non-genetic diagnoses

Say residual risk out loud with the assumptions : ethnicity prior used, detection rate, genes included, and whether a familial variant is known.

Why Negative Screening Is Not Zero

Imperfect analytic/clinical sensitivity: A 95% detection screen leaves ~5% of carriers undetected before Bayes normalization.

Limited gene set: A CFTR-only discussion does not clear risk for a phenotypically overlapping different gene.

Variant-type blind spots: Some methods miss large deletions/duplications, deep intronic variants, or certain structural events unless del/dup or alternate assays are included.

Wrong test for the family: Panel screening ≠ testing for a known familial pathogenic variant .

Misassigned prior: Using a pan-ethnic prior when a high-risk ancestry prior applies understates pre-test risk and can distort residual counseling.

Teaching comparison: Prior 1/25, detection 95% → posterior ≈ 1/481 (Section 2.3). Counseling line: "Your chance of being a carrier is now about 1 in 480 , not zero."

When to Offer Additional Testing

Offer or escalate testing when residual risk or clinical stakes remain material:

Situation Preferred next step Rationale

Familial pathogenic variant known in relative Site-specific testing for that variant Screening panels can miss the family's variant or report it differently

High residual carrier risk + pregnancy plans Partner carrier testing; consider diagnostic prenatal options if both high risk Converts individual residual risk into couple risk

Negative targeted screen, ancestry or phenotype suggests broader risk Expanded next-generation sequencing of the relevant gene(s), including del/dup as indicated Improves detection beyond targeted variant lists

XL family, woman with intermediate posterior Molecular carrier testing of the familial variant or full gene analysis per indication Clinical/Bayes numbers guide urgency but genotyping clarifies

Affected proband never genotyped Test the affected person first when available Identifies the familial variant that makes relatives' testing definitive

Uninformative VUS-only results Do not treat VUS as pathogenic; use phenotype, segregation, and lab reclassification pathways Avoids mismanaging residual risk on uncertain variants

Worked Couple Residual Risk

Consultand posterior carrier risk after negative screen ≈ 1/480 . Partner untested with population carrier risk 1/25 .

  • Approximate couple both-carrier probability ≈ (1/480)×(1/25) = 1/12,000
  • Affected-child risk ≈ (1/12,000)×(1/4) = 1/48,000

If the partner then screens negative with the same 95% detection and a 1/25 prior, his posterior is also ≈ 1/481. Couple affected risk ≈ (1/481)×(1/481)×(1/4) ≈ 1/926,000 (order-of-magnitude teaching). The plan may shift from "partner testing urgently" to "residual risk is very low; still offer education about limitations."

If the partner tests positive , the consultand's residual 1/480 suddenly matters: affected risk ≈ (1/480)×1×(1/4) = 1/1,920 , and prenatal/diagnostic options should be reviewed.

Follow-Up Medical Plans Beyond the Laboratory

Residual-risk visits should produce a concrete plan:

Who to test next (partner, affected relative, parents for phasing/de novo assessment).

Which assay (site-specific, sequencing, del/dup, biochemical).

Reproductive options if residual couple risk is unacceptable to the patient (CVS/amnio for known variants, IVF with PGT-M when a familial variant is characterized, donor gametes, adoption)—presented non-directively.

Phenotype-first surveillance when genotype is uninformative but empiric risks remain (for example, cancer syndrome differentials with uninformative panels—coordinate with Domain 1C concepts).

Cascade letters / relative contact when a pathogenic variant is found; residual-risk counseling for negatives in the cascade uses site-specific sensitivity near-ceiling, not population screening residuals.

Recontact policy: detection rates and gene lists change; document that reinterpretation may alter residual risk.

Counseling Language That Matches Board Expectations

Replace "You're negative, so you're fine" with "Your residual carrier risk is approximately X because the test detects about Y% of carriers."

Separate assay limitation from patient identity —negative results are about test performance, not personal failure.

For XL manifesting-carrier nuances or AR mild genotypes, clarify that residual risk discussions concern the defined phenotype in the stem.

When numbers are tiny, still offer the option of partner testing if it would change decisions; autonomy includes declining further testing.

Integrating the Whole Domain 2A Sequence

  • Step Output
  • Pedigree construction Who is at risk; inheritance hypothesis
  • Mendelian calculation Prior risk by position
  • Bayesian update Posterior given negative/positive conditional data
  • Residual risk + plan Actionable next medical steps and reproductive counseling

Exam vignettes often ask for the best next step rather than the fraction alone. If two answers both quote a plausible residual risk, choose the one that pairs the number with the correct assay and relative to test.

High-Yield Pitfalls

Declaring zero risk after a negative expanded panel when an affected relative's variant remains untested or unknown

Offering only reassurance when a partner is a known carrier and the consultand has nontrivial residual risk

Using screening residual-risk math after a negative site-specific test for a known familial variant (those residuals are typically laboratory-quality discussions, not 1/480-style population Bayes)

  • Ignoring consanguinity or shared ancestry that raises partner prior above population figures
  • Forgetting to update the plan when an affected family member finally receives a molecular diagnosis

Residual risk is the counseling product patients remember. Make it numeric, assumption-transparent, and paired with a follow-up medical plan.